Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women

Climacteric

Volumn 13, Issue 4, 2010, Pages 340-346

  Sidelmann, J J ^a,b   Skouby, S O ^a,c   Vitzthum, F ^d   Schwarz, H ^d   Jespersen, J ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Department of Clinical Biochemistry Hospital of South West Denmark ^*  (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Siemens Healthcare Diagnostics Products GmbH   (Germany)

Author keywords

Atherosclerosis; Factor VII activating protease; Hormone therapy; Menopause

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7 ACTIVATING PROTEINASE; CYPROTERONE ACETATE; ESTRADIOL VALERATE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; PLACEBO; PROTEINASE; UNCLASSIFIED DRUG; ESTRADIOL; HABP2 PROTEIN, HUMAN; SERINE PROTEINASE;

ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION; ADULT; AGE; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED CLINICAL TRIAL; CORONARY DISEASE; ENZYMOLOGY; ESTROGEN THERAPY; MIDDLE AGED; RISK FACTOR;

ADULT; AGE FACTORS; CORONARY DISEASE; CYPROTERONE ACETATE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; NORETHINDRONE; PLACEBOS; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 77953603499     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697131003597027     Document Type: Article

References (30)

1. Lowe GD. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J Intern Med 2004;256:361-374
2. Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study. BJOG 2003;110:541-547
3. Bladbjerg EM, Skouby SO, Andersen LF, Jespersen J. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 2002;17:3235-3241
4. Bladbjerg EM, Madsen JS, Kristensen SR, et al. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003;1:1208-1214
5. Hodis HN, Mack WJ, Lobo R. What is the cardioprotective role of hormone replacement therapy? Curr Atheroscler Rep 2003;5:56-66
6. van deWeijerPH.Risks of hormone therapy in the 50-59 year age group. Maturitas 2008;60:59-64
7. Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric 2008;11:355-363
8. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465-1477
9. Rees M, Stevenson J. Primary prevention of coronary heart disease in women. Menopause Int 2008;14:40-45
10. Lobo RA. Postmenopausal hormones and coronary artery disease: potential benefits and risks. Climacteric 2007; 10(Suppl 2):21-26
11. Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol 2008;51:564-580
12. Barlow DH. The medical management of menopause: to treat or not to treat? Ann NY Acad Sci 2008;1127:134-139
13. Kanse SM, Parahuleva M, Muhl L, Kemkes-Matthes B, Sedding D, Preissner KT. Factor activating protease (FSAP): vascular functions and role in atherosclerosis. Thromb Haemost 2008;99:286-289
14. Romisch J, Feussner A, Vermohlen S, Stohr HA. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1999;10:471-479
15. Sidelmann JJ, Vitzthum F, Funding E, Munster AM, Gram J, Jespersen J. Factor VII-activating protease in patients with acute deep venous thrombosis. Thromb Res 2008; 122:848-853
16. Kannemeier C, Al Fakhri N, Preissner KT, Kanse SM. Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells. FASEB J 2004;18:728-730
17. Parahuleva MS, Kanse SM, Parviz B, et al. Factor seven activating protease (FSAP) expression in human monocytes and accumulation in unstable coronary atherosclerotic plaques. Atherosclerosis 2008;196:164-171
18. Ireland H, Miller GJ, Webb KE, Cooper JA, Humphries SE. The factor VII activating protease G511E (Marburg) variant and cardiovascular risk. Thromb Haemost 2004;92:986-992
19. Franchi F, Martinelli I, Biguzzi E, Bucciarelli P, Mannucci PM. Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. Blood 2006;107:1731 (Pubitemid 43242416)
20. Weisbach V, Ruppel R, Eckstein R. The Marburg I polymorphism of factor VII-activating protease and the risk of venous thromboembolism. Thromb Haemost 2007;97:870-872
21. van Minkelen R, de Visser MC, Vos HL, Bertina RM, Rosendaal FR. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. Blood 2005;105:4898
22. Hoppe B, Tolou F, Radtke H, Kiesewetter H, Dorner T, Salama A. Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood 2005;105:1549-1551 (Pubitemid 40223673)
23. Hoppe B, Tolou F, Dorner T, Kiesewetter H, Salama A. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population. Thromb Haemost 2006;96:465-470
24. Hoppe B, Dorner T, Kiesewetter H, Salama A. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006;95:907-908
25. Gulesserian T, Hron G, Endler G, Eichinger S, Wagner O, Kyrle PA. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism. Thromb Haemost 2006;95:65-67
26. Willeit J, Kiechl S, Weimer T, et al. Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis. Circulation 2003; 107:667-670
27. Skouby SO, Gram J, Andersen LF, Sidelmann J, Petersen KR, Jespersen J. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002;186: 969-977
28. Stephan S, Schwarz H, Borchert A, et al. Tests for the measurement of factor VII-activating protease (FSAP) activity and antigen levels in citrated plasma, their correlation to PCR testing, and utility for the detection of the Marburg I-polymorphism of FSAP. Clin Chem Lab Med 2008;46:1109-1116
29. Phillips LS, Langer RD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005;83:558-566
30. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602